Synthetic Cohort Generation for Feasibility Testing Automation

Manual trial feasibility analysis is a high-stakes bottleneck, forcing sponsors to either query limited real-world data pools or rely on error-prone manual estimates, risking costly protocol amendments and enrollment delays. A custom synthetic cohort generation workflow automates this by creating statistically robust, privacy-safe patient populations from aggregated, de-identified source data. This allows for unlimited scenario testing—adjusting inclusion/exclusion criteria, simulating rare phenotypes, and modeling geographic distribution—without ever exposing protected health information (PHI) or violating data use agreements, turning months of speculative planning into days of data-driven modeling.

Implementation integrates with Veeva Vault, Medidata, and RWE platforms, using generative models (e.g., GANs, VAEs) conditioned on therapeutic-area ontologies. The architecture requires rigorous fidelity validation agents to check synthetic outputs against known epidemiological distributions and a governed review gate with biostatisticians before any downstream use. This creates a closed-loop system where protocol designers can stress-test assumptions, forecast enrollment curves, and optimize study design with quantifiable confidence, dramatically reducing the operational and financial risk of trial startup.

The workflow is triggered by a new trial protocol draft or a feasibility assessment request. An orchestrator, typically built with LangGraph or a custom Python service, ingests the protocol's inclusion/exclusion criteria and target disease parameters. It then dispatches parallel tasks to query aggregated, de-identified real-world data (RWD) sources—such as claims data lakes or tokenized EHR warehouses—to establish baseline statistical distributions for key patient attributes like age, comorbidities, and biomarker prevalence.

Synthetic records are generated using conditional generative models (GANs) or LLMs fine-tuned on medical ontologies, conditioned on the derived distributions. A dedicated validation agent performs statistical fidelity checks and clinical plausibility reviews against known medical knowledge graphs. Approved synthetic cohorts are loaded into a dedicated data lake and integrated with trial design tools like Medidata or Veeva for simulation. The final output is a feasibility dashboard detailing projected cohort size, demographic spread, and potential enrollment gaps, providing sponsors with a data-driven go/no-go signal without privacy exposure.

This workflow automates the creation of synthetic patient cohorts to de-risk trial design and site selection before exposing real PHI. It ingests aggregated, de-identified patient profiles and protocol criteria, then uses generative models to produce a statistically faithful synthetic dataset. The operational upside is clear: sponsors can model enrollment rates, test inclusion/exclusion logic, and identify protocol flaws without legal risk or manual data-use agreement negotiations, compressing months of feasibility planning into days.

Implementation integrates with Veeva Vault, Medidata RAVE, and custom trial design tools via API orchestration. The core architecture uses a LangGraph or CrewAI agent to manage the generative pipeline—typically a GAN or variational autoencoder—validated against real-world distributions for key clinical variables. Controls include automated bias detection, differential privacy guarantees, and a mandatory human-in-the-loop review gate before any simulation output informs a go/no-go decision, ensuring scientific and operational rigor.

Synthetic cohort generation automates the creation of statistically valid, privacy-safe patient datasets to model protocol feasibility before engaging sites or querying real EHRs. The workflow ingests aggregated, de-identified population health data and uses generative AI models—like GANs or diffusion models—conditioned on target disease prevalence, demographics, and biomarker distributions. This replaces manual, spreadsheet-based modeling, providing sponsors with a high-fidelity digital twin of the potential patient population to forecast enrollment rates, identify protocol bottlenecks, and optimize inclusion criteria with zero privacy risk.

Implementation integrates with RWE platforms like TriNetX or Flatiron and trial design software (e.g., Medidata Architect). The orchestrator, built with LangGraph, manages the generation loop, triggers validation agents that check statistical fidelity against real-world distributions, and routes outputs. Governance requires automated bias detection, version control of synthetic datasets, and audit trails linking each cohort to the source parameters and validation metrics, ensuring the synthetic data is a credible proxy for operational planning and regulatory discussions.

The business case is clear: manual feasibility studies are slow, expensive, and risk exposing PHI. A custom synthetic cohort workflow automates the creation of a statistically valid digital twin of your target population using generative models trained on aggregated, de-identified data. This allows you to stress-test inclusion/exclusion criteria, model enrollment rates, and identify protocol bottlenecks in days, not months, before engaging a single site or touching real patient records. The operational upside is faster study startup, lower protocol amendment risk, and a data-driven go/no-go decision.

Implementation requires a pipeline architecture. The orchestrator ingests protocol logic and aggregated RWE, triggering specialized generative agents (e.g., CTGAN for tabular data, diffusion models for synthetic imaging). A validation agent runs statistical tests (distribution matching, correlation preservation) and clinical plausibility checks against known ontologies. Outputs feed directly into trial design software via APIs. Critical controls include governance gates before any real-data query, synthetic data watermarking, and continuous monitoring for model drift to ensure the synthetic proxy remains a reliable predictor of real-world enrollment dynamics.